Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma

Inclusion Criteria: * Diagnosis of advanced or metastatic soft tissue sarcoma * Treatment with trabectedin in an in-label prescription * Age at least 18 years (inclusive) at the first visit * Patients with a life expectancy of at least 6 months * The informed consent form must be signed before any study specific tests or procedures are done * Confirmation of the subject's health insurance coverage prior to the first visit * Ability to understand and follow study-related instructions Exclusion Criteria: * ECOG PS \>2 * Estimated life expectancy of less than 6 months * Patients with STS not receiving trabectedin * Contraindications according to the local SmPC of Yondelis® * Subject is in custody by order of an authority or a court of law * Exclusion periods from other studies or simultaneous participation in other clinical studies * Previous assignment to treatment during this study * Close affiliation with the investigator (e.g. a close relative) or persons working at the study site * Subject is an employee of GWT-TUD GmbH or Pharma Mar S.A. * Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the subject's safety